Volume 15, Issue 10 (12-2017)
IJRM 2017, 15(10): 661-668 |
Back to browse issues page
1- Department of Physiology, Faculty of Biological Sciences, Shahid Beheshti University, Tehran, Iran
2- Department of Physiology, Faculty of Biological Sciences, Shahid Beheshti University, Tehran, Iran , homayoun_khazai@yahoo.com
3- Research and Clinical Center for Infertility, Yazd Reproduction Sciences Institute, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
2- Department of Physiology, Faculty of Biological Sciences, Shahid Beheshti University, Tehran, Iran , homayoun_khazai@yahoo.com
3- Research and Clinical Center for Infertility, Yazd Reproduction Sciences Institute, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
Abstract: (5444 Views)
Background: Citrullus colocynthis (CCT) is used as the anti-diabetic and antioxidant agent. Polycystic ovarian syndrome (PCOS) is a reproductive disorder which level of gonadotropins and sexual hormones are imbalanced.
Objective: We evaluated the effect of CCT hydro-alcoholic extract on hormonal and folliculogenesis process in estradiol valerate-induced PCOs rats’ model.
Materials and Methods: 40 female adult Wistar rats divided into five groups (n=8each: Group I (control) only injected by sesame oil as estradiol valerate solvent, group II (Sham) was orally received normal saline after estradiol valerate- induced polycystic ovarian syndrome (4 mg/rat estradiol valerate, intramuscularly), and three experimental groups, that after induction of PCOS within 60 days, received orally 50 mg/kg CCT extract (group III), 50mg/kg metformin (group IV), and CCT extract+ metformin (group V) for 20 days. The serum concentration level of luteinizing, testosterone and follicle stimulating hormones were measured using ELISA method and the serum concentration level of glucose were measured using the oxidative method (glucose meter). Histological study of ovary tissue carried out by hematoxylin-eosin staining.
Results: There was a significant reduction in luteinizing hormone and testosterone in III-V groups compared to Sham group, whereas follicle stimulating hormone in III-V groups was not significantly changed in comparison with Sham group. Histological investigations showed a significant increase in number of preantral and antral follicles and corpus luteum in the experimental groups compared to group II.
Conclusion: Marked improvement in hormonal and histological symptoms of PCOS may be due to CCT effects hence, CCT can potentially be considered as an effective drug for treatment of PCOS
Objective: We evaluated the effect of CCT hydro-alcoholic extract on hormonal and folliculogenesis process in estradiol valerate-induced PCOs rats’ model.
Materials and Methods: 40 female adult Wistar rats divided into five groups (n=8each: Group I (control) only injected by sesame oil as estradiol valerate solvent, group II (Sham) was orally received normal saline after estradiol valerate- induced polycystic ovarian syndrome (4 mg/rat estradiol valerate, intramuscularly), and three experimental groups, that after induction of PCOS within 60 days, received orally 50 mg/kg CCT extract (group III), 50mg/kg metformin (group IV), and CCT extract+ metformin (group V) for 20 days. The serum concentration level of luteinizing, testosterone and follicle stimulating hormones were measured using ELISA method and the serum concentration level of glucose were measured using the oxidative method (glucose meter). Histological study of ovary tissue carried out by hematoxylin-eosin staining.
Results: There was a significant reduction in luteinizing hormone and testosterone in III-V groups compared to Sham group, whereas follicle stimulating hormone in III-V groups was not significantly changed in comparison with Sham group. Histological investigations showed a significant increase in number of preantral and antral follicles and corpus luteum in the experimental groups compared to group II.
Conclusion: Marked improvement in hormonal and histological symptoms of PCOS may be due to CCT effects hence, CCT can potentially be considered as an effective drug for treatment of PCOS
Keywords: Polycystic ovary syndrome, Gonadotropins hormones, Follicugenesis, Rat Citrullus colocynthis
Type of Study: Original Article |
References
1. Atiomo WU, El-Mahdi E, Hardiman P. Familial associations in women with polycystic ovary syndrome. Fertil Steril 2003; 80: 143-145. [DOI:10.1016/S0015-0282(03)00502-8]
2. Hassanzadeh Bashtian M, Emami SA, Mousavifar N, Esmaily HA, Mahmoudi M, Mohammadpoor AH. Evaluation of fenugreek (Trigonella Foenum-graceum L.), effects seeds extract on insulin resistance in women with polycystic ovarian syndrome. Iran J Pharm Res 2013; 12: 475-481.
3. Sheikhha MH, Kalantar SM. Diagnostic criteria in polycystic ovary syndrome. In: Polycystic ovary syndrome. Edited by: Allahbadia GN, Agrawal R. Anshan Ltd, Kent, UK. 2007, 27-32.
4. Rotterdam E, Group A-SPCW. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004; 81: 19-25. [DOI:10.1016/j.fertnstert.2003.10.004]
5. Munir, I, Yen HW, Geller DH, Torbati D, Bierden RM, Weitsman SR, et al. Insulin augmentation of 17α-hydroxylase activity is mediated by phosphatidyl inositol 3-kinase but not extracellular signal-regulated kinase-1/2 in human ovarian theca cells. Endocrinology 2004; 145: 175-183. [DOI:10.1210/en.2003-0329]
6. Baillargeon JP, Carpentier A. Role of insulin in the hyperandrogenemia of lean women with polycystic ovary syndrome and normal insulin sensitivity. Fertil Steril 2007; 88: 886-893. [DOI:10.1016/j.fertnstert.2006.12.055]
7. Clark AM, Ledger W, Galletly C, Tomlinson L, Blaney F, Wang X, et al. Weight loss results in significant improvement in pregnancy and ovulation rates in anovulatory obese women. Hum Reprod 1995; 10: 2705-2712. [DOI:10.1093/oxfordjournals.humrep.a135772]
8. Kiddy DS, Hamilton-Fairley D, Bush A, Short F, Anyaoku V, Reed MJ, et al. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin Endocrinol 1992; 36: 105-111. [DOI:10.1111/j.1365-2265.1992.tb02909.x]
9. Rebar R, Judd HL, Yen SS, Rakoff J, Vandenberg G, Naftolin F. Characterization of the inappropriate gonadotropin secretion in polycystic ovary syndrome. J Clin Invest 1976; 57: 1320-1329. [DOI:10.1172/JCI108400]
10. Van Santbrink EJ, Hop WC, Fauser BC. Classification of normogonadotropic infertility: polycystic ovaries diagnosed by ultrasound versus endocrine characteristics of polycystic ovary syndrome. Fertil Steril 1997; 67: 452-458. [DOI:10.1016/S0015-0282(97)80068-4]
11. Fauser BC, Pache TD, Lamberts SW, Hop WC, de Jong FH, Dahl KD. Serum bioactive and immunoreactive luteinizing hormone and follicle-stimulating hormone levels in women with cycle abnormalities, with or without the polycystic ovarian disease. J Clin Endocrinol Metab 1991; 73: 811-817. [DOI:10.1210/jcem-73-4-811]
12. Amorim CA, David A, Dolmans MM, Camboni A, Donnez J, Van Langendonckt A. Impact of freezing and thawing of human ovarian tissue on follicular growth after long-term xenotransplantation. J Assist Reprod Genet 2011; 28: 1157-1165. [DOI:10.1007/s10815-011-9672-z]
13. Diamanti-Kandarakis E, Argyrakopoulou G, Economou F, Kandaraki E, Koutsilieris M. Defects in insulin signaling pathways in ovarian steroidogenesis and other tissues in polycystic ovary syndrome (PCOS). J Steroid Biochem Mol Biol 2008; 109: 242-246. [DOI:10.1016/j.jsbmb.2008.03.014]
14. Nestler JE. Insulin regulation of human ovarian androgens. Hum Reprod 1997; 12 (suppl.): 53-62. [DOI:10.1093/humrep/12.suppl_1.53]
15. Diamanti-Kandarakis E, Kouli CR, Bergiele AT, Filandra FA, Tsianateli TC, Spina GG, et al. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab 1999; 84: 4006-4011. [DOI:10.1210/jcem.84.11.6148]
16. Sheikhha MH, Kalantar SM, Ghasemi N. Genetics of Polycystic Ovary Syndrome. Iran J Reprod Med 2007; 5: 1-5.
17. Mehdizadeh A, Sheikhha MH, Kalantar SM, Aali BS, Ghanei A. Mutation analysis of exon1 of bone morphogenetic protein-15 gene in Iranian patients with polycystic ovarian syndrome. Int J Reprod Biomed 2016; 14: 527-532.
18. Bendjeddou D, Lalaoui K, Satta D. Immunostimulating activity of the hot water-soluble polysaccharide extracts of Anacyclus pyrethrum, Alpinia galanga and Citrullus colocynthis. J Ethnopharmacol 2003; 88: 155-160. [DOI:10.1016/S0378-8741(03)00226-5]
19. Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961; 21: 1440-1447. [DOI:10.1210/jcem-21-11-1440]
20. Abdel-Hassan IA, Abdel-Barry JA, Tarig Mohammeda S. The hypoglycaemic and antihyperglycaemic effect of Citrullus colocynthis fruit aqueous extract in normal and alloxan diabetic rabbits. J Ethnopharmacol 2000; 71: 325-330. [DOI:10.1016/S0378-8741(99)00215-9]
21. Ziyyat A, Legssyer A, Mekhfi H, Dassouli A, Serhrouchni M, Benjelloun W. Phytotherapy of hypertension and diabetes in oriental Morocco. J Ethnopharmacol 1997; 58: 45-54. [DOI:10.1016/S0378-8741(97)00077-9]
22. Benariba N, Djaziri R, Bellakhdar W, Belkacem N, Kadiata M, Malaisse WJ, et al. Phytochemical screening and free radical scavenging activity of Citrullus colocynthis seeds extracts. Asian Pac J Trop Biomed 2013; 3: 35-40. [DOI:10.1016/S2221-1691(13)60020-9]
23. Barth A, Müller D, Dürrling K. In vitro investigation of a standardized dried extract of Citrullus colocynthis on liver toxicity in adult rats. Exp Toxicol Pathol 2002; 54: 223-230. [DOI:10.1078/0940-2993-00252]
24. Marzouk B, Marzouk Z, Fenina N, Bouraoui A, Aouni M. Anti-inflammatory and analgesic activities of Tunisian Citrullus colocynthis Schrad. Immature fruit and seed organic extracts. Eur Rev Med Pharmacol Sci 2011; 15: 665-672.
25. Huseini HF, Darvishzadeh F, Heshmat R, Jafariazar Z, Raza M, Larijani B. The clinical investigation of Citrullus colocynthis (L.) schrad fruit in treatment of Type II diabetic patients: a randomized, double blind, placebo-controlled clinical trial. Phytother Res 2009; 23:1186-1189. [DOI:10.1002/ptr.2754]
26. Sharma A, Sharma P, Chaturvedi M, Joshi SC. Contraceptive efficacy of Citrullus colocynthis methanolic extract in male rats. Am J Phytomed clin Therap 2014; 2: 229-241.
27. Thakor AP, Patel AJ. Normalizing of estrous cycle in polycystic ovary syndrome (PCOS) induced rats with Tephrosia purpurea (Linn.) Pers. J Appli Natur Sci 2014; 1: 197-201.
28. Ullah N, Khan MA, Asif AH, Khan T, Ahmad W. Citrullus colocynthis failed to combat against renal derangements, in spite of its strong antioxidant properties. Acta Pol Pharm 2013; 70: 533-538.
29. Babaei H, Roshangar L, Sakhaee E, Abshenas J, Kheirandish R, Dehghani R. Ultrastructural and morphometrical changes of mice ovaries following experimentally induced copper poisoning. Iran Red Crescent Med J 2012; 14: 558-568.
30. Ehrmann DA. Polycystic ovary syndrome. N Engl J Med 2005; 352: 1223-1236. [DOI:10.1056/NEJMra041536]
31. Delazar A, Gibbons S, Kosari AR, Nazemiyeh H, Modarresi M, Nahar L, et al. Flavone C-glycosides and cucurbitacin glycosides from Citrullus colocynthis. DARU J Pharm Sci 2006; 14: 109-114.
32. Giwa S, Abdullah LC, Adam NM. Investigating "Egusi" (Citrullus colocynthis L.) seed oil as potential biodiesel feedstock. Energies 2010; 3: 607-618. [DOI:10.3390/en3040607]
33. Wang Z, Zhai D, Zhang D, Bai L, Yao R, Yu J, et al. Quercetin Decreases Insulin Resistance in a Polycystic Ovary Syndrome Rat Model by Improving Inflammatory Microenvironment. Reprod Sci 2017; 24: 682-690. [DOI:10.1177/1933719116667218]
34. Shah KN, Patel SS. Phosphatidylinositide 3-kinase inhibition: A new potential target for the treatment of polycystic ovarian syndrome. Pharm Biol 2016; 54: 975-983. [DOI:10.3109/13880209.2015.1091482]
35. Sivalingam VN, Myers J, Nicholas S, Balen AH, Crosbie EJ. Metformin in reproductive health, pregnancy and gynaecological cancer: established and emerging indications. Hum Reprod Update 2014; 20: 853-868. [DOI:10.1093/humupd/dmu037]
36. Nelson VL, Qin K-n, Rosenfield RL, Wood JR, Penning TM, Legro RS, et al. The biochemical basis for increased testosterone production in theca cells propagated from patients with polycystic ovary syndrome. J Clin Endocrinol Metab 2001; 86: 5925-5933. [DOI:10.1210/jcem.86.12.8088]
37. Diamanti-Kandarakis E. Polycystic ovarian syndrome: pathophysiology, molecular aspects and clinical implications. Ex Rev Mol Med 2008; 10.
38. Poretsky L, Cataldo NA, Rosenwaks Z, Giudice LC. The insulin-related ovarian regulatory system in health and disease. Endocr Rev 1999; 20: 535-582. [DOI:10.1210/edrv.20.4.0374]
39. Puder JJ, Varga S, Kraenzlin M, De Geyter C, Keller U, Muller B. Central fat excess in polycystic ovary syndrome: relation to low-grade inflammation and insulin resistance. J Clin Endocrinol Metab 2005; 90: 6014-6021. [DOI:10.1210/jc.2005-1002]
40. González F, Rote N, Minium J, Kirwan JP. In vitro evidence that hyperglycemia stimulates tumor necrosis factor-α release in obese women with polycystic ovary syndrome. J Endocrinol 2006; 188: 521-529. [DOI:10.1677/joe.1.06579]
41. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 1995; 95: 2409-2415. [DOI:10.1172/JCI117936]
42. Liang Y-C, Huang Y-T, Tsai S-H, Lin-Shiau S-Y, Chen C-F, Lin J-K. Suppression of inducible cyclooxygenase and inducible nitric oxide synthase by apigenin and related flavonoids in mouse macrophages. Carcinogenesis 1999; 20: 1945-1952. [DOI:10.1093/carcin/20.10.1945]
43. Havsteen BH. The biochemistry and medical significance of the flavonoids. Pharmacol Ther 2002; 96: 67-202. [DOI:10.1016/S0163-7258(02)00298-X]
44. Kim HP, Son KH, Chang HW, Kang SS. Anti-inflammatory plant flavonoids and cellular action mechanisms. J Pharmacol Sci 2004; 96: 229-245. [DOI:10.1254/jphs.CRJ04003X]
45. Jonard S, Dewailly D. The follicular excess in polycystic ovaries, due to intra-ovarian hyperandrogenism, may be the main culprit for the follicular arrest. Hum Reprod Update 2004; 10: 107-117. [DOI:10.1093/humupd/dmh010]
46. Willis DS, Watson H, Mason HD, Galea R, Brincat M, Franks S. Premature response to luteinizing hormone of granulosa cells from anovulatory women with polycystic ovary syndrome: relevance to mechanism of anovulation. J Clin Endocrinol Metab 1998; 83: 3984-3991. [DOI:10.1210/jc.83.11.3984]
47. Jakimiuk AJ, Weitsman SR, Navab A, Magoffin DA. Luteinizing hormone receptor, steroidogenesis acute regulatory protein, and steroidogenic enzyme messenger ribonucleic acids are overexpressed in thecal and granulosa cells from polycystic ovaries. J Clin Endocrinol Metab 2001; 86: 1318-1323.
48. Willis DS, Watson H, Mason HD, Galea R, Brincat M, Franks S. Premature Response to Luteinizing Hormone of Granulosa Cells from Anovulatory Women with Polycystic Ovary Syndrome: Relevance to Mechanism of Anovulation. J Clin Endocrinol Metab 1998; 83: 3984-3991. [DOI:10.1210/jc.83.11.3984]
49. Loumaye E, Engrand P, Shoham Z, Hillier SG, Baird DT. Clinical evidence for an LH "ceiling"effect induced by administration of recombinant human LH during the late follicular phase of stimulated cycles in World Health Organization type I and type II anovulation. Hum Reprod 2003; 18: 314-322. [DOI:10.1093/humrep/deg066]
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |